SCHEMBL22200519

SCHEMBL22200519

CSc1ncc2cc(-c3cc(F)c(NSCc4ccccc4)c(F)c3F)c(=O)n(C(C)C)c2n1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 3/20 0.42
BTK Q06187 3/20 0.35
WEE1 P30291 3/20 0.33
ABL1 P00519 3/20 0.33
FGFR1 P11362 1/20 0.33
SIK1 P57059 1/20 0.32
SIK2 Q9H0K1 1/20 0.32
SIK3 Q9Y2K2 1/20 0.32
CDK4 P11802 1/20 0.31
CCND1 P24385 1/20 0.31
CCND2 P30279 1/20 0.31
CCND3 P30281 1/20 0.31
MAPT P10636 2/20 0.31
RXFP1 Q9HBX9 1/20 0.31
BRAF P15056 1/20 0.30
SRC P12931 2/20 0.30
LYN P07948 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22200564 0.91 ERN1 (0.39) ERN1BTKWEE1ABL1MAPT
SCHEMBL22200701 0.90 ERN1 (0.42) ERN1BTKWEE1ABL1FGFR1
SCHEMBL22200333 0.88 ERN1 (0.46) ERN1BTKWEE1ABL1FGFR1
SCHEMBL22200335 0.81 WEE1 (0.34) ERN1WEE1ABL1FGFR1MAPT
SCHEMBL22200561 0.81 ERN1 (0.39) ERN1BTKWEE1ABL1FGFR1
SCHEMBL22200534 0.80 ERN1 (0.39) ERN1FGFR1BRAFSRC
SCHEMBL22190811 0.79 ERN1 (0.50) ERN1BTKWEE1ABL1BRAF
SCHEMBL29356779 0.79 ERN1 (0.50) ERN1BTKWEE1ABL1BRAF
SCHEMBL22200371 0.79 PIK3CA (0.38) BTKABL1FGFR1BRAFSRC
SCHEMBL22191061 0.78 ERN1 (0.35) ERN1BTKABL1SIK1SIK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020142612-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. GENENTECH, INC. (US) 2020-07-09 WO disclosed